Steven N. Goodman

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Steven N Goodman
CitizenshipAmerican
EducationAB, Harvard College, Biochemistry, Applied Math (1976)
Alma materHarvard University
New York University;
Known for"Cancer research: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents".
Scientific career
FieldsMedical Research, Epidemiology, Medical Statistics
Thesis (1989)

Steven N. Goodman is an American Professor of Medicine and of Health Research and Policy (Epidemiology) at Stanford School of Medicine.[1] He has extensively contributed to statistics and probability analysis within the biosciences, and in 1999 he coined the term "p-value fallacy".[2]

Life[edit]

He graduated with an AB (Bachelor of Arts) from Harvard College in 1976, majoring in Biochemistry and Applied Math. He received an MD from New York University in 1981, completed a pediatrics residency at Washington University in St. Lous, qualified as a Pediatrician in 1985, received an MHS, Biostatistics (1987) and a PhD (1989) Epidemiology from Johns Hopkins School of Public Health.

Co-founder and co-director, along with John Ioannidis, of the Meta-Research Innovation Center at Stanford (METRICS). At Stanford, he is the Associate Dean of Clinical and Translational Research, and Chief of the Division of Epidemiology.

Awards[edit]

Works[edit]

He has made numerous contributions to the methods of clinical research, comparative effectiveness, meta analysis and scientific inference.[3][4][5][6][7][8][9][10][11][12][13][14] in addition to works on scientific evidence.[15][16][17][18][19][20][21][22][23][24][25][26][27][28]

References[edit]

  1. ^ "Steven Goodman".
  2. ^ Sellke, Thomas; Bayarri, M. J; Berger, James O (February 2001). "Calibration of ρ Values for Testing Precise Null Hypotheses". The American Statistician. 55 (1): 62–71. doi:10.1198/000313001300339950.
  3. ^ Cornell, J. E., Mulrow, C. D., Localio, R., Stack, C. B., Meibohm, A. R., Guallar, E., Goodman, S. N. (2014). "Random-Effects Meta-analysis of Inconsistent Effects: A Time for Change". Annals of Internal Medicine. 160 (4): 267–270. doi:10.7326/M13-2886.
  4. ^ Basch, E., Aronson, N., Berg, A., Flum, D., Gabriel, S., Goodman, S. N., Helfand, M., Ioannidis, J. P., Lauer, M., Meltzer, D., Mittman, B., Newhouse, R., Normand, S., Schneeweiss, S., Slutsky, J., Tinetti, M., Yancy, C. (2012). "Methodological Standards and Patient-Centeredness in Comparative Effectiveness Research The PCORI Perspective". JAMA. 307 (15): 1636–1640. doi:10.1001/jama.2012.466. PMID 22511692.
  5. ^ Goodman, S. N. (2012). "Quasi-random reflections on randomized controlled trials and comparative effectiveness research". Clinical Trials. 9 (1): 22–26. doi:10.1177/1740774511433285.
  6. ^ Sox, H. C., Goodman, S. N. (2012). "The Methods of Comparative Effectiveness Research". Annual Review of Public Health. 33: 425–445. doi:10.1146/annurev-publhealth-031811-124610.
  7. ^ Goodman, S., Dickersin, K. (2011). "Metabias: A Challenge for Comparative Effectiveness Research". Annals of Internal Medicine. 155 (1): 61–U104. doi:10.7326/0003-4819-155-1-201107050-00010. PMID 21727295.
  8. ^ Luce, B. R., Kramer, J. M., Goodman, S. N., Connor, J. T., Tunis, S., Whicher, D., Schwartz, J. S. (2009). "Rethinking Randomized Clinical Trials for Comparative Effectiveness Research: The Need for Transformational Change". Annals of Internal Medicine. 151 (3): 206–W45. doi:10.7326/0003-4819-151-3-200908040-00126.
  9. ^ Goodman SN, Greenland S (2007). "Assessing the unreliability of the medical literature: A response to "Why most published research findings are false"". Archived from the original on 2012-04-06.
  10. ^ Goodman, S. N. (2002). "The mammography dilemma: A crisis for evidence-based medicine?". Annals of Internal Medicine. 137 (5): 363–365. doi:10.7326/0003-4819-137-5_part_1-200209030-00015.
  11. ^ Goodman, S. N., Zahurak, M. L., PIANTADOSI, S. (1995). "SOME PRACTICAL IMPROVEMENTS IN THE CONTINUAL REASSESSMENT METHOD FOR PHASE-I STUDIES". Statistics in Medicine. 14 (11): 1149–1161. doi:10.1002/sim.4780141102.
  12. ^ Goodman, S. N., Berlin, J. A. (1994). "THE USE OF PREDICTED CONFIDENCE-INTERVALS WHEN PLANNING EXPERIMENTS AND THE MISUSE OF POWER WHEN INTERPRETING RESULTS". Annals of Internal Medicine. 121 (3): 200–206. doi:10.7326/0003-4819-121-3-199408010-00008.
  13. ^ Goodman, S. N. (1989). "META-ANALYSIS AND EVIDENCE". Controlled Clinical Trials. 10 (2): 188–204. doi:10.1016/0197-2456(89)90030-5. PMID 2666026.
  14. ^ Goodman, S. N., Royall, R. (1988). "EVIDENCE AND SCIENTIFIC-RESEARCH". American Journal of Public Health. 78 (12): 1568–1574. doi:10.2105/ajph.78.12.1568. PMC 1349737.
  15. ^ Glass, T. A., Goodman, S. N., Hernán, M. A., Samet, J. M. (2013). "Causal inference in public health". Annual Review of Public Health. 34: 61–75. doi:10.1146/annurev-publhealth-031811-124606. PMC 4079266. PMID 23297653.
  16. ^ Faden, R. R., Kass, N. E., Goodman, S. N., Pronovost, P., Tunis, S., Beauchamp, T. L. (2013). "An Ethics Framework for a Learning Health Care System: A Departure from Traditional Research Ethics and Clinical Ethics". Hastings Center Report. 43: S16–S27. doi:10.1002/hast.134.
  17. ^ Kass, N. E., Faden, R. R., Goodman, S. N., Pronovost, P., Tunis, S., Beauchamp, T. L. (2013). "The Research-Treatment Distinction: A Problematic Approach for Determining Which Activities Should Have Ethical Oversight". Hastings Center Report. 43: S4–S15. doi:10.1002/hast.133.
  18. ^ Mello, M. M., Goodman, S. N., Faden, R. R. (2012). "Ethical Considerations in Studying Drug Safety - The Institute of Medicine Report". New England Journal of Medicine. 367 (10): 959–964. doi:10.1056/NEJMhle1207160. PMID 22913661.
  19. ^ Goodman, S. (2011). "Confessions of a chagrined trialist". BMJ Quality & Safety. 20: I97–I98. doi:10.1136/bmjqs.2010.046623. PMC 3066790.
  20. ^ Goodman, S. N. (2007). "Stopping at nothing? Some dilemmas of data monitoring in clinical trials". Annals of Internal Medicine. 146 (12): 882–887. doi:10.7326/0003-4819-146-12-200706190-00010.
  21. ^ Laine, C., Goodman, S. N., Griswold, M. E., Sox, H. C. (2007). "Reproducible research: Moving toward research the public can really trust". Annals of Internal Medicine. 146 (6): 450–453. doi:10.7326/0003-4819-146-6-200703200-00154.
  22. ^ Goodman, S. N., Sladky, J. T. (2005). "A Bayesian approach to randomized controlled trials in children utilizing information from adults: the case of Guillain–Barre syndrome". Clinical Trials. 2 (4): 305–310. doi:10.1191/1740774505cn102oa.
  23. ^ Goodman, S. N. (2001). "Of P-values and bayes: A modest proposal". Epidemiology. 12 (3): 295–297. doi:10.1097/00001648-200105000-00006.
  24. ^ Goodman, S. N. (1999). "Toward evidence-based medical statistics. 1: The P value fallacy". Annals of Internal Medicine. 130 (12): 995–1004. doi:10.7326/0003-4819-130-12-199906150-00008. PMID 10383371.
  25. ^ Goodman, S. N. (1999). "Toward evidence-based medical statistics. 2: The Bayes factor". Annals of Internal Medicine. 130 (12): 1005–1013. doi:10.7326/0003-4819-130-12-199906150-00019. PMID 10383350.
  26. ^ Goodman, S. N., Berlin, J., Fletcher, S. W., Fletcher, R. H. (1994). "MANUSCRIPT QUALITY BEFORE AND AFTER PEER-REVIEW AND EDITING AT ANNALS OF INTERNAL-MEDICINE". Annals of Internal Medicine. 121 (1): 11–21. doi:10.7326/0003-4819-121-1-199407010-00003. PMID 8198342.
  27. ^ Goodman, S. N. (1993). "P-VALUES, HYPOTHESIS TESTS, AND LIKELIHOOD - IMPLICATIONS FOR EPIDEMIOLOGY OF A NEGLECTED HISTORICAL DEBATE". American Journal of Epidemiology. 137 (5): 485–496.
  28. ^ Goodman, S. N. (1992). "A COMMENT ON REPLICATION, P-VALUES AND EVIDENCE". Statistics in Medicine. 11 (7): 875–879. doi:10.1002/sim.4780110705.